Bicycle Therapeutics plc (BCYC) Misses Q1 EPS by 22c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Bicycle Therapeutics plc (BCYC) Misses Q1 EPS by 22c

Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023 7:00 AM EDT

- Continued progress across pipeline, including encouraging BT8009 Phase I dose escalation results presented in Q123

- Entered into a strategic collaboration with Novartis and expanded separate collaboration with the Division of Radiopharmaceutical Chemistry, German Cancer Research Center to develop Bicycle® Radio-Conjugates

- Cash position of $293.8 million at March 31, 2023 excludes $50 million upfront payment from Novartis, and is expected to provide financial runway into 2025

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and... More